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Context. 
Current  guidelines  for  the  treatment  of  Hepatic  Encephalopathy  (HE) suggest that 
ammonia  reduction  is  the  main  focus  of  therapy.  The  conceptual  framework  for 
ammonia lowering is based upon strategies to reduce its generation and absorption in 
the colon through the use of lactulose and reduced protein diet.
Starting point. 
Two  recently  published  studies  provide  compelling  and  provocative  data  that 
questions  the  relevance  of  these  interventions.  The  first  is  a  systematic  review  of 
randomised  trials  of  non-absorbable  disaccharides  in  the  treatment  of  HE  by  Als-
Nielsen  et  al.  which  concluded  that  there  is  ‘insufficient  evidence’  to  determine 
whether non-absorbable disaccharides are of benefit to patients with HE. The second 
is a small randomised study by Cordoba et al. which showed that diets with normal 
protein content can be administered safely to cirrhotics with episodic HE and that 
protein restriction does not have any beneficial effect for cirrhotic patients during an 
episode of HE.
Where next?
Two simultaneous approaches to developing new therapies for HE are needed. Firstly, 
it is important to focus upon the interorgan metabolism of ammonia. Indeed, data 
from  recent  studies  suggest  that  the  small  intestine  and  kidneys  are  important 
ammonia producers and the muscle is an important organ that can remove ammonia. 
Novel therapeutic approaches targeting these organs reduce ammonia. Secondly, new 
research  is  urgently  needed  to  explore  factors  other  than  ammonia  that  may  be 
important  in  the  pathogenesis  of  HE  and  recent  studies  point  to  the  important 
synergistic role of inflammation.Conclusion.
The lack of conclusive data about the therapeutic efficacy of any treatment regime 
supports  the  view  that  placebo-controlled  trials  of  newer  agents  are  both  urgently 
needed and ethical. Currently, the emphasis of treatment of HE should shift from 
existing therapies to aggressive management of the precipitating event.Hepatic  encephalopathy  (HE)  remains  a  major  clinical  problem  in  patients  with 
cirrhosis  and  is  the  feature  that  defines  the  prognosis  of  patients  with acute  liver 
injury.  In  acute  liver  failure  (ALF)  rapid  deterioration  in  consciousness  level  and 
increased  intracranial  pressure  may  result  in  brain  herniation  and  death.  The 
manifestations of HE in cirrhosis seriously affect the quality of life of patients and 
impair daily functioning in both the physical and psychological domains. When HE is 
severe in cirrhosis, patients may develop varying degrees of confusion and coma. (1) 
Since the initial description of ammonia in the pathogenesis of HE over 100 
years ago, more than 1200 papers have explored it’s role and confirmed that ammonia 
is central in the pathogenesis of HE. In patients with severe liver dysfunction and 
therefore  impaired  urea  synthesis,  glutamine  is  synthesised  from  ammonia  and 
glutamate and, acts as a major alternative ammonia detoxification pathway. Glutamine 
synthesis  occurs  within  astrocytes  and  causes  brain  swelling.  The  degree  of  brain 
swelling  was  shown  to  correlate  with neuropsychological function and normalised 
after  liver  transplantation.  (2)  More  recently,  direct  evidence  for  the  ammonia-
glutamine-brain  swelling  hypothesis  of  HE  has  been  provided  in  patients  with
cirrhosis. (3) 
Current  therapies  for  HE  are  based  upon  ammonia lowering strategies. Up 
until now this has been based on the hypothesis that the colon is the primary organ
responsible for the generation of ammonia. Therefore the mainstay of current therapy 
of HE are non-absorbable antibiotics, lactulose and protein restricted diets. However, 
the results of two recently published studies (4;5) suggest that the colon may not be 
the  only  focus  for  ammonia  reduction  indicating  that  the  role  of  other  organs  in 
ammonia metabolism needs to be explored.LACTULOSE IN HE:
Traditionally, the colon has been thought of as the major site of ammonia production 
and  lactulose/lactitol  has  been  considered  the  standard  of  care  to  which  all  other 
newer  therapies  have  had  to  be  compared  to.  Its  use  was  prompted  by  studies 
suggesting that the colonic bacterial flora is the main source of ammonia production in 
the body. (6) Colonic bacteria are thought to produce ammonia by splitting urea and 
possibly  amino  acids.  (7)  With  this  in  mind,  poorly  absorbed  antibiotics  such  as 
neomycin were introduced and lactulose was introduced as a safer alternative. (8)  On 
the basis of 2 small trials, lactulose was considered as effective as neomycin. (9;10)
Hence for over 25 years, non-absorbable disaccharides have been considered as the first 
line pharmacological treatment for HE. 
In the recently published systematic review of 22 randomised trials using non-
absorbable disaccharides (lactulose/lactitol) for HE, Als-Nielsen et al. conclude that 
there is ‘insufficient’ evidence at present to recommend or refute the use of them in 
HE.  (4)  Compared  with  placebo  or  no  intervention,  lactulose/lactitol  had  no 
significant effect on mortality. Only 4 placebo-controlled trials were considered of 
high enough quality and in these trials a total of 57 patients were included (Table 1). 
Only  low  quality  trials  in  patients  with  minimal  HE  found  that  lactulose  had  a 
beneficial  effect  as  assessed  by  various  non-validated  psychometric  tests. 
Furthermore, although it was shown that lactulose/lactitol was inferior to antibiotics 
such  as  neomycin  and  rifamixin,  in  reducing  the  risk  of  no  improvement  and  of 
lowering  blood  ammonia  concentration,  there  was  no  significant  difference  in 
mortality. 
This  review  has  important  implications  and  qualifies  that  non-absorbable 
disaccharides  have  been  introduced  into  clinical  practice  without  the  appropriate evidence  base.  Moreover,  most  randomised  trials  of  new  treatments  for  HE  use 
lactulose as a comparator and performing large placebo-controlled trials has so far 
been viewed as unethical. 
PROTEIN RESTRICTION IN HE:
Historically, protein restriction for the treatment of HE has been advocated based on 
anecdotal observations. (11) This is in direct opposition to the fact that in cirrhosis, 
higher protein intakes are required to maintain a positive nitrogen balance. Cordoba et 
al. showed in a small randomised study in 20 cirrhotic patients with HE that diets with 
a  normal  protein  content  can  be  administered  safely.  (5)  Ten  patients  underwent 
protein restriction followed by progressive increments, whilst 10 followed a normal 
protein diet (1.2g/kg/day). Enteric nutrition was delivered by a nasogastric tube for 2 
weeks. The low protein group received no protein for the first 3 days, increasing every 
3 days until 1.2 g/kg/day for the last 2 days. Both groups received the same amount of 
calories.    Protein  metabolism  was  studied  on  days  2  and  14  with  the  glycine-N15 
infusion method and showed that protein synthesis was similar in the low and normal 
protein groups but protein breakdown was higher in the low-protein group. The lack 
of any significant differences between the two groups in the course of HE and the 
reduced protein breakdown in the normal protein group argues against the restriction 
of protein in patients with HE. However, the results of this study should be confirmed 
in a larger trial as it was not adequately powered.
FUTURE DIRECTIONS:
(a) Other Organs:
Given that the metabolic capacity of the liver to remove ammonia is severely curtailed 
in liver disease, a reduction in ammonia concentration will require one to focus upon 
the different organs involved in its metabolism. (Figure 1) (i) Gut: It has become clear that the small intestine is an important source 
of  ammonia  generation  through  the  uptake  of  glutamine.  (12)  The 
observation  of  hyperammonemia  and  HE  in  germ-free  dogs  with  a 
portacaval  shunt  suggests  that  colonic  bacteria  play  a  limited  role  in 
producing  ammonia.  (13)  The  enterocytes  have  a  high  glutaminase 
activity making them a major ammonia producing site during breakdown 
of glutamine. Indeed, in patients with cirrhosis, glutamine uptake and 
ammonia production has been demonstrated, and increased glutaminase 
activity was shown to correlate with the severity of minimal HE. (14) 
Therefore, the small intestine may be a new target for therapy.
(ii) Kidneys: The kidneys possess the ability to both produce ammonia 
and also to excrete it. (15) During hyperammonemia the kidneys switch 
from net ammonia production to net ammonia excretion. (16) Recently, 
studies in patients with cirrhosis have shown that the kidneys are an 
important target. Volume expansion in cirrhotics produces significant 
increases in renal ammonia excretion resulting in a reduction in plasma 
ammonia  concentration.  This  was  shown  to  improve  mental  state 
supporting the notion that the kidneys can be manipulated favorably. 
(17)  
(iii) Muscle: During  the  hyperammonemic  state,  muscle  detoxifies 
ammonia  through  conversion  to  glutamine.  (12;16)  L-ornithine  L-
aspartate  (LOLA),  which  is  a  mixture  of  2  amino  acids,  provides 
intermediates  that  increase  glutamate  availability  for  synthesis  of 
glutamine  and  illustrates  the  concept  that  muscle  can  detoxify 
ammonia. Administration into animals with ALF resulted in reduced brain water (18) and into patients with HE resulted in an improvement 
in HE compared with placebo-treated controls. (19) However the jury 
with respect to the efficacy of LOLA in HE is still out, as only 3 of the 
11 trials using LOLA have been fully published. (20)
(b) Other Factors:
Although  we  know  that  ammonia  is  critical  in  the  pathogenesis  of  HE,  clinical 
observations do not always show a consistent correlation between the concentration of 
ammonia  in  the  blood  and  the  manifest  symptoms  of  HE.  (21)  Therefore,  it  is 
probable  that  other  factors  in  addition  to  hyperammonemia  are  important  in 
modulating the effects of hyperammonemia.
(i) Inflammation: Recently the role of inflammation on the development of 
HE has been highlighted. Sepsis is a frequent precipitant of HE and studies 
have suggested rapid progression in the severity of HE in those patients with 
ALF  that  have  more  marked  inflammation.  These  observations  have  been 
confirmed in cirrhotic patients. (22) Nitric oxide, proinflammatory cytokines 
and free radicals are all therefore possible targets. Measurement of circulating 
inflammatory  mediators  may  prove  useful  in  evaluating  the  systemic
inflammatory  response  and  assist  in  tailoring  the  administration  of  anti-
inflammatory  agents.  Altering  the  gut  flora  and  modulation  of  the  gut 
permeability may justify the use of probiotic therapy. (23)
The use of a ‘detoxification device’ in liver failure might lead to a 
temporary  improvement  in  the  patient’s  condition,  allowing  the  liver  to 
recover  spontaneously.  Liver  support  systems,  such  as  The  Molecular 
Adsorbents Recirculating System (MARS) may have a role. MARS has been 
found to be of benefit in improving HE grade in patients with decompensated cirrhosis independently of changes in ammonia and cytokines. (24) Therefore 
other  toxins  such  as  nitric  oxide,  oxygen-based  free  radicals  and 
endocannibinoids may be important. 
(ii) Cerebral Blood Flow: Cerebral hyperemia is critical in the development 
of  intracranial  hypertension  in  ALF.  (25)  Moderate  hypothermia  has  been 
shown to be useful in the treatment of an uncontrolled increase in intracranial 
pressure  in  patients  with  ALF  by  reducing  cerebral  blood  flow.  (26)  In 
cirrhosis,  changes  in  regional  cerebral  blood  flow  may  account  for  the 
attention deficit that is a characteristic feature of minimal HE. (27) Recent 
evidence suggests that an acute increase in ammonia alters regional cerebral 
blood flow and this is associated with memory deficits. (28)
CONCLUSIONS:
We have entered an exciting phase in HE research with novel therapies evolving from 
the discovery of new targets. Current evidence supports the view that lactulose and 
low protein diets should no longer be part of standard care in patients with HE but this 
does  not  necessarily  mean  that  these  therapies  do  not  work  in  selected  patients.
Further trials of lactulose, protein restriction and newer agents should be placebo-
controlled.  Given  that  the  variability  in  the  improvement  of  HE  with  placebo  is 
between 20-40%, power calculations will be difficult and a multicentre approach will 
be necessary to enroll adequate numbers of patients. Current guidelines will need to 
be revised with strict attention being paid to treating the precipitating factors, with 
correction  of  dehydration,  electrolyte  and  acid-base  imbalance,  constipation  and 
infection.
FIGURE LEGENDFigure 1
A diagrammatic representation to show the inter-organ trafficking of ammonia 
in health, and in cirrhosis. In healthy individuals the liver removes ammonia 
by detoxification into urea. In patients with cirrhosis, the metabolic capacity of 
the liver is reduced resulting in hyperammonemia. In this situation the muscle 
becomes an important organ of ammonia detoxification into glutamine. This 
glutamine acts as a temporary buffer which has the potential to both regenerate 
ammonia (enterocytes) and also to excrete ammonia (kidneys). This highlights 
the  importance  of  organs  such  as  the  gut,  kidney  and  muscle  in  the
homeostasis of ammonia levels in patients with liver disease.Reference List
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